“Korean biopharmaceutical companies should use U.S. federal government’s R&D support programs”

It was suggested it would be important for Korean biopharmaceutical companies to actively use the Federal Government of the United States’ R&D support program.

Jung-Min Lee at Korea Trade-Investment Promotion Agency(KOTRA) Washington gave an advice in the most recent issue of the KOTRA’s foreign market news ‘Federal Government of the United States’ Investment into Life Science R&D and Opportun...